INTRODUCTION: myasthenia gravis (MG) is a rare disease affecting the neuromuscular junction. It can lead to a life-threatening condition, especially when it is associated with respiratory failure. Full remission is possible with treatment. Our aims are to describe the clinical course of patients with MG with under treatment, in order to further improve management and to implement a database of patients living in Madagascar. METHODS: we conducted a descriptive retrospective study in the Department of Neurology at the Befelatanana Antananarivo University Hospital Center between January 2010 and December 2017. This study involved all patients diagnosed with MG based on positive prostigmin test. RESULTS: among the 5814 hospitalized patients, 25 (0,42%) were included. Only 16 patients were on follow-up (64%) of whom 14 were receiving medical treatment. Three of them had undergone thymectomy. The mean follow-up period was 24 months. Among treated patients, 8 improved and 2 died. Among thymectomized patients, 2 improved and 1 died. CONCLUSION: myasthenia gravis is a rare but serious disease. Improvement is possible with treatment even in the absence of adequate technical equipment for its management in Madagascar. Currently, a campaign in partnership with Myasthenia Gravis Association in Madagascar is underway for breathing devices useful especially when myasthenic crises occur. Copyright: Santatra Ratsitohara Razafindrasata et al.
INTRODUCTION: myasthenia gravis (MG) is a rare disease affecting the neuromuscular junction. It can lead to a life-threatening condition, especially when it is associated with respiratory failure. Full remission is possible with treatment. Our aims are to describe the clinical course of patients with MG with under treatment, in order to further improve management and to implement a database of patients living in Madagascar. METHODS: we conducted a descriptive retrospective study in the Department of Neurology at the Befelatanana Antananarivo University Hospital Center between January 2010 and December 2017. This study involved all patients diagnosed with MG based on positive prostigmin test. RESULTS: among the 5814 hospitalized patients, 25 (0,42%) were included. Only 16 patients were on follow-up (64%) of whom 14 were receiving medical treatment. Three of them had undergone thymectomy. The mean follow-up period was 24 months. Among treated patients, 8 improved and 2 died. Among thymectomized patients, 2 improved and 1 died. CONCLUSION: myasthenia gravis is a rare but serious disease. Improvement is possible with treatment even in the absence of adequate technical equipment for its management in Madagascar. Currently, a campaign in partnership with Myasthenia Gravis Association in Madagascar is underway for breathing devices useful especially when myasthenic crises occur. Copyright: Santatra Ratsitohara Razafindrasata et al.
Authors: Emanuela Taioli; Philip Kent Paschal; Bian Liu; Andrew J Kaufman; Raja M Flores Journal: Ann Thorac Surg Date: 2016-10-27 Impact factor: 4.330
Authors: Andrew J Kaufman; Justin Palatt; Mark Sivak; Peter Raimondi; Dong-Seok Lee; Andrea Wolf; Fouad Lajam; Faiz Bhora; Raja M Flores Journal: Semin Thorac Cardiovasc Surg Date: 2016-04-16
Authors: Julie S Hansen; Ditte H Danielsen; Finn E Somnier; Trine Frøslev; Johannes Jakobsen; Søren P Johnsen; Henning Andersen Journal: Muscle Nerve Date: 2015-06-03 Impact factor: 3.217
Authors: Donald B Sanders; Gil I Wolfe; Michael Benatar; Amelia Evoli; Nils E Gilhus; Isabel Illa; Nancy Kuntz; Janice M Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David P Richman; Jan Verschuuren; Pushpa Narayanaswami Journal: Neurology Date: 2016-06-29 Impact factor: 9.910